ProKidney (PROK) Competitors $2.34 +0.10 (+4.24%) As of 12:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PROK vs. PTGX, SRRK, HCM, APLS, MOR, IMVT, KYMR, CRNX, CPRX, and RAREShould you be buying ProKidney stock or one of its competitors? The main competitors of ProKidney include Protagonist Therapeutics (PTGX), Scholar Rock (SRRK), HUTCHMED (HCM), Apellis Pharmaceuticals (APLS), MorphoSys (MOR), Immunovant (IMVT), Kymera Therapeutics (KYMR), Crinetics Pharmaceuticals (CRNX), Catalyst Pharmaceuticals (CPRX), and Ultragenyx Pharmaceutical (RARE). These companies are all part of the "pharmaceutical products" industry. ProKidney vs. Its Competitors Protagonist Therapeutics Scholar Rock HUTCHMED Apellis Pharmaceuticals MorphoSys Immunovant Kymera Therapeutics Crinetics Pharmaceuticals Catalyst Pharmaceuticals Ultragenyx Pharmaceutical ProKidney (NASDAQ:PROK) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings. Which has higher earnings and valuation, PROK or PTGX? Protagonist Therapeutics has higher revenue and earnings than ProKidney. ProKidney is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProKidney$80K8,543.18-$61.19M-$0.60-3.89Protagonist Therapeutics$209.18M16.70$275.19M$0.7080.23 Does the media prefer PROK or PTGX? In the previous week, Protagonist Therapeutics had 9 more articles in the media than ProKidney. MarketBeat recorded 19 mentions for Protagonist Therapeutics and 10 mentions for ProKidney. Protagonist Therapeutics' average media sentiment score of 0.71 beat ProKidney's score of 0.65 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProKidney 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protagonist Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate PROK or PTGX? ProKidney presently has a consensus target price of $6.25, suggesting a potential upside of 167.67%. Protagonist Therapeutics has a consensus target price of $67.20, suggesting a potential upside of 19.66%. Given ProKidney's higher probable upside, research analysts plainly believe ProKidney is more favorable than Protagonist Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProKidney 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40Protagonist Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is PROK or PTGX more profitable? Protagonist Therapeutics has a net margin of 24.88% compared to ProKidney's net margin of 0.00%. Protagonist Therapeutics' return on equity of 8.12% beat ProKidney's return on equity.Company Net Margins Return on Equity Return on Assets ProKidneyN/A N/A -15.03% Protagonist Therapeutics 24.88%8.12%7.41% Which has more risk & volatility, PROK or PTGX? ProKidney has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 2.33, suggesting that its stock price is 133% more volatile than the S&P 500. Do insiders & institutionals hold more shares of PROK or PTGX? 51.6% of ProKidney shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 41.5% of ProKidney shares are held by company insiders. Comparatively, 4.9% of Protagonist Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryProtagonist Therapeutics beats ProKidney on 14 of the 17 factors compared between the two stocks. Get ProKidney News Delivered to You Automatically Sign up to receive the latest news and ratings for PROK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PROK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PROK vs. The Competition Export to ExcelMetricProKidneyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$683.45M$2.47B$5.61B$9.81BDividend YieldN/A1.81%4.64%4.14%P/E Ratio-3.8921.9230.2025.55Price / Sales8,543.18717.96462.19105.95Price / CashN/A186.7137.7258.50Price / Book-0.684.518.486.05Net Income-$61.19M$31.61M$3.26B$265.02M7 Day Performance-18.92%2.42%3.14%2.39%1 Month Performance-48.57%3.82%5.64%3.50%1 Year Performance2.86%6.91%42.56%25.82% ProKidney Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PROKProKidney3.3612 of 5 stars$2.34+4.2%$6.25+167.7%+7.7%$683.45M$80K-3.893Earnings ReportUpcoming EarningsPTGXProtagonist Therapeutics1.8908 of 5 stars$53.82-0.1%$66.10+22.8%+34.3%$3.34B$434.43M71.76120Earnings ReportAnalyst RevisionSRRKScholar Rock4.497 of 5 stars$34.62-6.4%$44.14+27.5%+239.7%$3.29B$33.19M-13.68140News CoverageEarnings ReportAnalyst RevisionHigh Trading VolumeHCMHUTCHMED3.1653 of 5 stars$17.92-0.4%$28.00+56.3%-24.4%$3.13B$630.20M0.001,811Positive NewsAPLSApellis Pharmaceuticals4.647 of 5 stars$23.73-1.9%$36.83+55.2%-33.9%$3.00B$781.37M-13.04770MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730Positive NewsIMVTImmunovant2.2419 of 5 stars$15.96-3.3%$36.40+128.1%-48.7%$2.73BN/A-5.82120Trending NewsEarnings ReportAnalyst ForecastKYMRKymera Therapeutics3.0747 of 5 stars$41.35-3.8%$59.11+43.0%-6.2%$2.69B$47.07M-13.34170News CoverageEarnings ReportAnalyst RevisionCRNXCrinetics Pharmaceuticals3.3951 of 5 stars$28.53-2.4%$69.50+143.6%-42.5%$2.67B$1.04M-7.47210Earnings ReportAnalyst ForecastCPRXCatalyst Pharmaceuticals4.8792 of 5 stars$21.79-1.9%$32.83+50.7%+5.4%$2.66B$491.73M13.8880RAREUltragenyx Pharmaceutical4.4287 of 5 stars$28.05-3.0%$82.17+192.9%-44.8%$2.65B$560.23M-4.771,294Analyst RevisionHigh Trading Volume Related Companies and Tools Related Companies PTGX Alternatives SRRK Alternatives HCM Alternatives APLS Alternatives MOR Alternatives IMVT Alternatives KYMR Alternatives CRNX Alternatives CPRX Alternatives RARE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PROK) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProKidney Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProKidney With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access